Saredutant

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Saredutant
Accession Number
DB06660
Type
Small Molecule
Groups
Investigational
Description

Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

Structure
Thumb
Synonyms
Not Available
External IDs
SR 48968 / SR48968
Categories
UNII
720U2QK8I5
CAS number
142001-63-6
Weight
Average: 552.54
Monoisotopic: 551.2106328
Chemical Formula
C31H35Cl2N3O2
InChI Key
PGKXDIMONUAMFR-AREMUKBSSA-N
InChI
InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1
IUPAC Name
N-[(2S)-2-(3,4-dichlorophenyl)-4-(4-acetamido-4-phenylpiperidin-1-yl)butyl]-N-methylbenzamide
SMILES
CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1)C(=O)C1=CC=CC=C1

Pharmacology

Indication

Investigated for use/treatment in depression and anxiety disorders.

Pharmacodynamics
Not Available
Mechanism of action

Saredutant works by blocking the effects of Neurokinin A at the NK-2 receptor.

TargetActionsOrganism
USubstance-K receptorNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Saredutant is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Saredutant is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Saredutant is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Saredutant.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Saredutant is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Saredutant.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Saredutant is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Saredutant.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Saredutant is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
AcenocoumarolThe risk or severity of adverse effects can be increased when Saredutant is combined with Acenocoumarol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
94726
BindingDB
50071484
ChEMBL
CHEMBL308148
Wikipedia
Saredutant

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAnxiety1
3CompletedTreatmentDepressive Disorders3
3CompletedTreatmentGeneralized Anxiety2
3CompletedTreatmentMajor Depressive Disorder (MDD)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000115 mg/mLALOGPS
logP5.81ALOGPS
logP5.25ChemAxon
logS-6.7ALOGPS
pKa (Strongest Acidic)13.69ChemAxon
pKa (Strongest Basic)9.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.65 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity155.96 m3·mol-1ChemAxon
Polarizability58.3 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Benzamides / Dichlorobenzenes / Benzoyl derivatives / Aralkylamines / Aryl chlorides / Tertiary carboxylic acid amides / Acetamides / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives
show 6 more
Substituents
Phenylpiperidine / Benzamide / Benzoic acid or derivatives / Benzoyl / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Aryl halide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tachykinin receptor activity
Specific Function
This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order ...
Gene Name
TACR2
Uniprot ID
P21452
Uniprot Name
Substance-K receptor
Molecular Weight
44441.705 Da
References
  1. Ahlstedt I, Engberg S, Smith J, Perrey C, Moody A, Morten J, Lagerstrom-Fermer M, Drmota T, von Mentzer B, Pahlman I, Lindstrom E: Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants. Biochem Pharmacol. 2008 Aug 15;76(4):476-81. doi: 10.1016/j.bcp.2008.06.003. Epub 2008 Jun 13. [PubMed:18601911]
  2. Van Schoor J, Joos GF, Chasson BL, Brouard RJ, Pauwels RA: The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J. 1998 Jul;12(1):17-23. [PubMed:9701408]

Drug created on March 19, 2008 10:46 / Updated on September 02, 2019 18:22